The fibroblast growth factor (FGF) family is composed of 18 secreted signaling proteins
consisting of canonical FGFs and endocrine FGFs that activate four receptor tyrosine …

Within recent decades glucagon receptor (GcgR) agonism has drawn attention as a
therapeutic tool for the treatment of type 2 diabetes and obesity. In both mice and humans …

Objective Pharmacological strategies that engage multiple mechanisms-of-action have
demonstrated synergistic benefits for metabolic disease in preclinical models. One …

The pancreatic hormone, glucagon, is known to regulate hepatic glucose production, but
recent studies suggest that its regulation of hepatic amino metabolism is equally important …

Glucagon receptor (GCGR)-targeted multi-agonists are being developed for the treatment of
obesity and metabolic disease. GCGR activity is utilised for its favourable weight loss and …

Background and Purpose Glucagon‐like peptide‐1 (GLP‐1) and glucagon (GCG) receptor
dual agonist have promising therapeutic effects in the treatment of obesity and diabetes …

Abstract Fibroblast growth factor 21 (FGF21) was originally identified as an important
metabolic regulator which plays a crucial physiological role in regulating a variety of …

Objective Treatment with glucagon receptor antagonists (GRAs) reduces blood glucose but
causes dyslipidemia and accumulation of fat in the liver. We investigated the acute and …

(1) Background: Proglucagon-derived peptides (PDGPs) including glucagon (Gcg), GLP-1,
and GLP-2 regulate lipid metabolism in the liver, adipocytes, and intestine. However, the …

A major challenge of obesity therapy is to sustain clinically relevant weight loss over time.
Achieving this goal likely requires both reducing daily caloric intake and increasing caloric …